spironolactone has been researched along with everolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Peiró, I; Simó-Servat, A; Villabona, C | 1 |
| Kream, RM; Ming, Y; Stefano, GB; Zhuang, Q | 1 |
1 review(s) available for spironolactone and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for spironolactone and everolimus
| Article | Year |
|---|---|
Corticotropin secreting pancreatic neuroendocrine tumour, a therapeutic management challenge. A presentation of 2 cases.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Chromogranins; Combined Modality Therapy; Embolization, Therapeutic; Everolimus; Female; Fludrocortisone; Humans; Hydrocortisone; Ketoconazole; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Peptides, Cyclic; Phenylurea Compounds; Quinolines; Somatostatin; Spironolactone; Splenectomy; Sunitinib | 2019 |
Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies.
Topics: Calcineurin; Calcineurin Inhibitors; Cyclosporine; Diabetes Complications; Diabetes Mellitus; Everolimus; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mineralocorticoid Receptor Antagonists; Sirolimus; Spironolactone; Tacrolimus; Transplantation Tolerance | 2019 |